超越他类药物:降低LDL胆固醇和心血管事件的新药学目标
Emanuel Raschi1, Manuela Casula2, Arrigo F G Cicero3
1Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Pharmacology & therapeutics
|August 11, 2023
概括
更新的药物提供了创新的方法来降低低密度脂蛋白胆固醇 (LDL-C) 对动脉样硬化心血管疾病 (ASCVD) 的风险. 本综述详细介绍了它们的药理学,益处和风险,以指导临床实践.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 脂质学 脂质学是指脂质学.
背景情况:
- 失脂症是动脉样硬化心血管疾病 (ASCVD) 的一个关键可修改的风险因素.
- 目前的失脂症治疗指南强调基于ASCVD风险的低密度脂蛋白胆固醇 (LDL-C) 降低强度.
- 关于最佳的脂质标和治疗策略 (逐步与上游治疗) 的争论仍在继续.
研究的目的:
- 提供基于证据的新型药理学药物治疗失脂血症的综述.
- 详细介绍新兴的LDL-C降低药物的药理学方面,益处风险概况和以患者为中心的优势.
- 通过尽量减少治疗惯性来支持临床实践,以控制失脂症.
主要方法:
- 对最近批准的LDL-C向药物的药理学方面的审查.
- 对益处风险概况的分析,包括对心血管终点的影响.
- 评估以患者为中心的优势,例如坚持.
主要成果:
- 现在有几种针对LDL-C的新型药物类别,包括PCSK9抑制剂,ACL抑制剂,ANGPTL3抑制剂和MTP抑制剂.
- 这些药物提供了超越他类药物和ezetimibe的创新作用机制.
- 了解它们的具体特征对于有效的临床应用至关重要.
结论:
- 新型药理学药物为治疗脱脂症和降低ASCVD风险提供了新的治疗选择.
- 对这些药物的药理学,疗效,安全性和患者影响的全面了解对于最佳的治疗选择至关重要.
- 这种知识使临床医生能够量身定制治疗,改善患者的坚持,并最终减少心血管事件.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
699
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
699
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:26Targets for Drug Action: Overview
6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K
01:26Coronary Artery Disease IV: Preventive Measures
24
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
24
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
561
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
561
01:27Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9